Popik Piotr, Holuj Malgorzata, Nikiforuk Agnieszka, Kos Tomasz, Trullas Ramon, Skolnick Phil
Behavioral Neuroscience and Drug Development, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343, Kraków, Poland,
Psychopharmacology (Berl). 2015 Mar;232(6):1025-38. doi: 10.1007/s00213-014-3738-4. Epub 2014 Sep 27.
In addition to the negative and positive symptoms of schizophrenia, cognitive deficits, including prefrontal cortical dysfunction, are now recognized as core features of this disorder. Compounds increasing the NMDA receptor function via the strychnine-insensitive glycine receptors have been proposed as potential antipsychotics. Depending on the ambient concentrations of glutamate and glycine, 1-aminocyclopropanecarboxylic acid (ACPC) behaves as either a partial agonist or a functional antagonist at the strychnine-insensitive glycine receptors.
We investigated the procognitive and antipsychotic-like effects of ACPC in rats treated with phencyclidine (PCP) or ketamine (KET), compounds that produce psychotic-like symptoms in humans and laboratory animals.
Cognitive effects were investigated in the novel object recognition (NOR) and attentional set-shifting tests (ASST). In addition, the effects of ACPC were investigated in PCP-induced hyperactivity, conditioned avoidance response (CAR), and prepulse inhibition (PPI) tests. The effects on attention and impulsivity were measured in the five-choice serial reaction time task (5-CSRTT).
ACPC (200-400 mg/kg) inhibited memory fading in naive rats and like clozapine prevented PCP- and KET-induced amnesia in the NOR. In naive animals, ACPC at 400 but not 200 mg/kg enhanced cognitive flexibility in the ASST, as the animals required fewer trials to reach the criteria during the extra-dimensional phase. In contrast, ACPC did not affect PCP-induced hyperactivity, CAR, and PPI as well as attention and impulsivity in the 5-CSRTT.
The present study demonstrates that ACPC enhanced both object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but did not affect impulsivity nor exhibit an antipsychotic-like profile.
除精神分裂症的阴性和阳性症状外,认知缺陷,包括前额叶皮质功能障碍,现在被认为是该疾病的核心特征。通过对士的宁不敏感的甘氨酸受体增加NMDA受体功能的化合物已被提议作为潜在的抗精神病药物。根据谷氨酸和甘氨酸的周围浓度,1-氨基环丙烷羧酸(ACPC)在对士的宁不敏感的甘氨酸受体上表现为部分激动剂或功能性拮抗剂。
我们研究了ACPC对用苯环己哌啶(PCP)或氯胺酮(KET)处理的大鼠的促认知和抗精神病样作用,PCP和KET在人类和实验动物中会产生类似精神病的症状。
在新颖物体识别(NOR)和注意力转换测试(ASST)中研究认知作用。此外,在PCP诱导的多动、条件性回避反应(CAR)和前脉冲抑制(PPI)测试中研究了ACPC的作用。在五选择连续反应时间任务(5-CSRTT)中测量对注意力和冲动性的影响。
ACPC(200-400mg/kg)抑制了未处理大鼠的记忆衰退,并且与氯氮平一样,可预防NOR中PCP和KET诱导的失忆。在未处理的动物中,400mg/kg而非200mg/kg的ACPC增强了ASST中的认知灵活性,因为动物在维度转换阶段达到标准所需试验次数更少。相比之下,ACPC不影响PCP诱导的多动、CAR和PPI以及5-CSRTT中的注意力和冲动性。
本研究表明,ACPC增强了依赖前额叶皮质的物体识别记忆和认知灵活性,但不影响冲动性,也未表现出抗精神病样特征。